Luspatercept-aamt Shows Efficacy Treating Anemia Due to Myelodysplastic Syndromes
June 19th 2023Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.
Read More